AKBA · Akebia Therapeutics, Inc.

The appointment of Philip Vickers brings decades of global biopharmaceutical R&D, corporate strategy, and business development experience to Akebia's leadership as the company advances its pipeline of kidney and rare disease therapies. Vickers previously held senior leadership roles at major firms including Shire, Pfizer, and Merck, as well as early-stage biotech companies. Steven Gilman's retirement follows his service guiding Akebia through the 2018 Keryx merger and the commercialization of Vafseo (vadadustat).